The Lion's Den · Male Hormone Health

Growth, Done Right

The honest guide to human growth hormone (HGH, the 191AA form).

HGH can be genuinely good for you or genuinely harmful. Almost the entire difference is the dose.

+2.1 kg
lean mass and -2.1 kg fat in trials (but partly water, and no strength gain in healthy adults)
U-shaped
IGF-1 risk: too low and too high both raise mortality
1 RCT
of HGH plus an insulin sensitizer exists (GH + metformin). The rest is theory or anecdote

Body comp: Liu et al., Ann Intern Med 2007. IGF-1 U-curve: Mukama et al., JCEM 2023. Combo: Herrmann et al., Horm Metab Res 2005.

Human growth hormone is one of the most hyped, most misunderstood, and most misused compounds in this whole space. The truth is more useful than the hype: used physiologically it can genuinely help, and pushed like a bodybuilder it can grow your organs and your risk along with your muscle.

This guide covers all of it: what 191AA HGH actually is, the real benefits, the real risks, the safe way to run it versus the way that gives men the distended "GH gut," and some out-of-the-box angles (like pairing it with an insulin sensitizer to offset its effect on blood sugar). We will be straight about your eyesight question too, since that is why some of you are here.

How to read the labels in this guide

We tag the evidence behind each claim so you always know what you are standing on:

Clinical = backed by a human or animal study, a meta-analysis, or a medical guideline (we cite it, with a link at the bottom).
Anecdotal = community, coach, or clinic reports and case stories. Useful for ideas, but not proof. We label it honestly and link where it came from.

Read this first

Education only, not medical advice. In the United States, using HGH for anti-aging or body composition is off-label and specifically restricted by federal law. Everything here is for research and educational purposes, adults 21 and over, and every dose named is an example for discussion with a licensed provider, never a prescription.

90-second self-check

Are you set up to run it the safe way?

A reflection tool, not a diagnosis. It just shows you how close your setup is to the physiologic "sweet spot" versus the danger end, and what to bring to a provider.

Your HGH safety reflection

Answer honestly.

Roughly what daily dose are you on (or considering)?

Are you tracking your bloodwork?

Which describe you? (tap all that apply)

Noticed any of these? (tap all that apply)

Education only, not a diagnosis. Your IGF-1, glucose, and history, read by your provider, are what actually decide this.

The basics

What 191AA HGH actually is

Your pituitary makes growth hormone as a single 191-amino-acid protein. Modern recombinant HGH (the drug somatropin) is manufactured to be identical to that native sequence, which is why it is marketed as "191AA." Clinical The older first-generation product carried an extra methionine (192 amino acids) and drew more anti-GH antibodies; and before recombinant HGH existed, GH was extracted from cadaver pituitaries and was withdrawn because it transmitted Creutzfeldt-Jakob (prion) disease. So 191AA is simply the clean, identical-to-your-own form.

HGH is not a GH "secretagogue" (this matters)

Two different things get lumped together:

  • 191AA HGH replaces the hormone. You inject the finished GH. Blood GH rises directly, in a non-pulsatile way, and your own pituitary output becomes irrelevant. It is the blunt, powerful, federally-restricted tool.
  • Secretagogues stimulate your own pituitary (CJC-1295, ipamorelin, tesamorelin, sermorelin, and oral MK-677). They largely preserve your natural pulse and the somatostatin "brake," which makes them gentler. We have a full separate guide on these; this report is about the exogenous hormone itself.

The plumbing, in one line

GH travels to the liver and tells it to make IGF-1, which is the main messenger that carries out most of GH's growth and repair effects. That is why IGF-1 is the number you actually monitor, not GH.

The full secretagogue breakdown

Two switches and one readout

Since 191AA replaces GH outright, it is worth knowing the gentler alternative in full: compounds that make your own pituitary release more GH, within your body's own physiologic limits. Think of it as two switches and one readout. One switch says "make and prime GH" (the GHRH analogs). The other says "release the GH you have got, and lift the brake" (the ghrelin-mimetic secretagogues). And IGF-1 is the single readout that tells you whether any of it is working.

Clinical Because secretagogues work through your own axis, they largely preserve the natural pulsatile rhythm and the somatostatin "brake" that shuts things down when GH runs high. That built-in ceiling is the core safety advantage over injecting the finished hormone. Clinical The mirror-image rule from the HGH data sheet: exogenous GH already supplies what a GHRH analog upstream-stimulates, so combining 191AA with a GHRH analog (tesamorelin, CJC-1295, sermorelin) is redundant. GH plus a ghrelin-mimetic (ipamorelin, a GHRP, or MK-677) is additive, not redundant, since they hit different steps.

CJC-1295 (with and without DAC)

Clinical (pharmacodynamics)

A long-acting GHRH analog: the "make and prime GH" switch. The DAC version binds serum albumin and lingers for days; no-DAC clears faster and closer to natural rhythm.

For
  • Dose-dependent 2 to 10x rises in GH and 1.5 to 3x rises in IGF-1 lasting days, in healthy adults (Teichman 2006)
  • No-DAC preserves more of the natural pulse than the long-acting DAC version
Against
  • DAC's multi-day elevation works against physiologic pulsatility, the exact thing secretagogues are supposed to preserve
  • No robust long-term adult-optimization outcome trials, just short pharmacodynamic studies

Note: redundant with exogenous HGH; additive with a ghrelin-mimetic like ipamorelin.

Ipamorelin

Clinical (pharmacology)

A selective ghrelin-receptor (GHS-R) agonist: the "release what you have, lift the brake" switch, without much appetite or cortisol pull.

For
  • Selective GH-releasing activity with less of the hunger/cortisol baggage of older GHRPs (Raun 1998)
  • Commonly paired with CJC-1295 no-DAC for a "prime and release" combo, 3 to 5x greater GH release than either alone in the underlying pharmacology
Against
  • No robust long-term human outcome trials (strength, body comp, longevity) at typical community doses
  • Not FDA-approved for any adult-optimization indication

Note: the most "gentle" of the group on paper, but still evidence-thin for real-world outcomes.

Tesamorelin

Clinical (FDA-approved indication)

A GHRH(1-44) analog, and the only one in this class with an actual FDA approval.

For
  • FDA-approved (Egrifta) for HIV-associated visceral fat accumulation, with real reductions in visceral adipose tissue across phase-3 trials in over 900 patients (Falutz 2007/2010)
  • The strongest, most clinically grounded compound in this entire secretagogue class
Against
  • The approval is for HIV lipodystrophy specifically; it does not automatically transfer to a healthy man's fat loss or anti-aging goals
  • Can raise blood sugar like any GH-axis compound

Note: redundant with exogenous HGH; additive with ipamorelin (this is the combo with the most legitimate clinical footing of the bunch).

Sermorelin

Mostly historical / anecdotal for adult use

GHRH(1-29), the first GHRH analog ever used clinically, largely superseded by tesamorelin and CJC-1295 no-DAC.

For
  • Long clinical history in pediatric GH testing and deficiency contexts; a known, well-characterized molecule
Against
  • Adult-optimization evidence is thin; it can be weak in older men or anyone with reduced pituitary reserve, since it only asks the pituitary to respond, it does not replace GH itself
  • Marketed as "gentler because it's natural-acting," which is plausible but not proof of a better outcome

Note: largely a legacy option; tesamorelin and CJC-1295 no-DAC have mostly replaced it.

MK-677 (ibutamoren)

Clinical (the best long-term human data, and a warning)

An oral ghrelin-mimetic secretagogue, no injections. Also the compound with the clearest 2-year human trial data in this class, and it is not flattering.

For
  • Oral, convenient; raised GH and IGF-1 into the young-adult range and increased fat-free mass over 2 years in older adults (Nass 2008)
Against
  • That same 2-year trial found no strength or functional benefit despite the fat-free-mass gain, and it worsened fasting glucose and reduced insulin sensitivity (Nass 2008) - it carries the same metabolic downside as the injectable options
  • Raises appetite noticeably; can cause fluid retention/edema like the rest of the class

Note: treat it as the "oral cousin" of HGH's metabolic risk profile, not a free pass just because it is a pill.

GHRPs (GHRP-2, GHRP-6) and hexarelin

Older generation / more side effects

Earlier ghrelin-mimetics than ipamorelin, generally with more off-target pull on appetite and cortisol.

For
  • Established pharmacology and a long history of use in research/clinical contexts
Against
  • GHRP-6 in particular drives significant hunger; GHRP-2 and hexarelin pull cortisol and prolactin more than the newer, more selective ipamorelin
  • Largely superseded by ipamorelin for exactly this reason

Note: if you are choosing in this family today, ipamorelin's selectivity is the reason it displaced these.

The honest bottom line on secretagogues

Secretagogues are gentler by design, not gentler by outcome data. Only tesamorelin has an actual FDA-approved indication behind it. MK-677 has the best long-term human numbers in the class, and those numbers show the same metabolic downside as injectable GH, just in pill form. The rest (CJC-1295, ipamorelin, sermorelin, the older GHRPs) rest on short pharmacodynamic studies, not outcome trials. "Works through your own pituitary" is a real safety advantage in mechanism; it is not the same as "proven safe and effective for a healthy man's goals."

Under the hood

How it works

01

GH signals the cell

GH binds its receptor and fires the JAK2/STAT5 pathway, which switches on growth genes, most importantly IGF-1.

02

IGF-1 does the work

Liver-made IGF-1 is the main effector: protein building, tissue growth, and repair. GH also acts directly to burn fat and blunt insulin.

03

The dual edge

Those two direct effects, lipolysis and insulin antagonism, are why GH leans you out but also pushes blood sugar up. Hold that thought.

Clinical Natural GH is released in pulses, biggest during deep sleep, and is switched off by high blood sugar and insulin. Injected HGH bypasses that rhythm, which is both its strength (reliable levels) and its risk (no built-in brake). A single random GH blood level is nearly useless; IGF-1 is the steady readout.

All the goods

The real benefits

The benefits are real, and they are strongest in people who are genuinely GH-deficient. In healthy adults the same changes happen but smaller, and with an honest catch worth knowing.

How strong is the evidence, by benefit?

A rough read of the human evidence quality, not a promise of your result.

Fat loss / lean mass
Strong
Tendon / collagen
Strong (underrated)
Lipids
Moderate
Bone density
Slow / modest
Skin, sleep, wellbeing
Suggestive
Strength (healthy adults)
Not shown

Liu 2007 (Ann Intern Med); Newman 2015 (Pituitary); Heinemeier 2012 (Scand J Med Sci Sports); Blackman 2002 (JAMA); Rudman 1990 (NEJM).

Body composition Clinical

The most consistent effect. In GH-deficient adults, roughly +2.6 kg lean and -2.2 kg fat (Newman 2015); in healthy elderly, about +2.1 kg lean and -2.1 kg fat with no net weight change (Liu 2007). The honest catch: a chunk of that early "lean mass" is retained water, and in healthy adults these gains did not translate into more strength or performance (Blackman 2002; the MK-677 trial, Nass 2008).

Tendon, collagen, and connective tissue Clinical (the underrated one)

The GH/IGF-1 axis stimulates collagen synthesis in tendon and connective tissue far more powerfully than it builds contractile muscle (Heinemeier 2012). This is a genuinely under-appreciated angle: HGH's value may be more about connective-tissue quality, skin, and joint/tendon resilience than about raw muscle. (For a specific torn rotator cuff, though, the healing evidence is mixed, so temper the injury-repair hype: Vaysman 2022.)

Skin, bone, lipids, sleep, wellbeing

Clinical Modest cholesterol/LDL improvement (not dose-dependent, Newman 2015); slow bone-density gains over 18 to 24+ months (Davidson 2004); a near-significant skin-thickness increase in the original Rudman 1990 study. Quality-of-life benefit is real and guideline-endorsed in diagnosed GH deficiency, but has not been shown in healthy adults. Clinical (emerging) There is also a growing liver angle: low-GH states track with fatty liver, and raising GH can reduce liver fat in some settings, though this is not yet a general "HGH for fatty liver" recommendation.

The honest distinction to carry through the whole guide

In a genuinely GH-deficient person, replacement gives clear, reproducible benefits. In a healthy adult, the same body-composition shifts happen but are smaller, do not add strength, and come with a higher side-effect rate. That gap is why no guideline endorses HGH as an anti-aging drug.

The real costs

Risks and side effects

  • Fluid retention, carpal tunnel, joint aches Clinical - the most common early effects, from GH holding onto sodium and water. Dose-dependent, worse in older/heavier men, and usually reversible when you lower the dose. This is also why some "lean mass" is water.
  • Insulin resistance and diabetes risk Clinical - GH is frankly diabetogenic. It raises blood sugar and can push insulin resistance, especially at higher doses and in men who already carry metabolic risk. This is the single most important downside to manage (see the companion section).
  • The IGF-1 / cancer question Clinical - IGF-1 makes cells grow and resists cell death, so the concern is real in principle. Higher IGF-1 is associated with modestly higher breast and prostate cancer risk, and both very low and very high IGF-1 raise overall mortality (the U-shaped curve, Mukama 2023). Replacement-dose HGH in deficient adults has not shown increased primary cancer, but that reassurance does not cover years of supra-normal IGF-1. Prior radiation or a cancer history is a clear red flag.
  • Acromegaly-spectrum changes Clinical - chronic GH excess grows soft tissue, bone, and organs: enlarged hands/feet, coarsened features, and heart enlargement (acromegalic cardiomyopathy). This is the model for what long-term megadosing imitates.
  • Raised intracranial pressure and vision Clinical - rare but real: new persistent headache or visual disturbance after starting GH warrants stopping and an eye/nerve check (papilledema).
  • Thyroid shift Clinical - GH speeds conversion of T4 to T3 and can unmask low thyroid, so free T4/T3 are worth checking after starting.
  • "More" is not "more healing." Clinical The clearest proof the dose is the danger: in critically ill adults, high-dose GH significantly increased death (Takala 1999, NEJM). That is a different population, but it demolishes the "if some is good, more is better" instinct that drives megadosing.

The heart of this guide

The safe route vs the way that grows your organs

You asked the right question, and the evidence answers it clearly: there is a safe route, and the danger is the dose and the duration, not the molecule. Keep IGF-1 in the middle and HGH behaves. Chase a supra-normal IGF-1 for years and you rebuild the acromegaly picture on purpose.

Done right

The safe, physiologic route

  • Low, titrated dosing aimed at keeping IGF-1 mid-normal for your age, not supra-normal. Clinical
  • Start low and go up slowly; ultra-low doses can be metabolically neutral or even helpful.
  • Monitor IGF-1, fasting glucose/A1c, blood pressure, and thyroid. Clinical
  • When IGF-1 is kept normal, comorbidity stays low and life expectancy is near-normal even in treated acromegaly. Clinical

The dangerous way

The bodybuilder megadose

  • Several IU a day, chasing a supra-normal IGF-1 for years. Anecdotal
  • Recreates the acromegaly spectrum: organ growth, heart enlargement, insulin resistance/diabetes. Clinical
  • The distended "GH gut" / palumboism (see below).
  • Often stacked with insulin, which multiplies the visceral-growth and blood-sugar risk. Anecdotal

"GH gut" / palumboism, honestly

The distended, pushed-out abdomen seen on some heavy bodybuilders is real to look at, but the cause is not as settled as the internet claims. Clinical The one academic paper on it screened over 1,200 studies and found no peer-reviewed study dedicated to it - it calls the causation "anecdotal," and lists proposed drivers as visceral fat, organ enlargement, and altered collagen (Suslin 2024). What is clinically established is that chronic GH excess (acromegaly) genuinely enlarges organs. Anecdotal The specific bodybuilding "HGH plus insulin grew my intestines" story is a reasonable extrapolation from that, but it is almost certainly multifactorial (organ/tissue growth + insulin-driven visceral fat + GH water retention + sheer food volume and muscle). Bottom line: do not run doses high enough to find out.

The real safety test is not the dose number

The sharpest way to know if you are running HGH the safe way is not the IU on the syringe. It is this: is your IGF-1 mid-normal, is your blood sugar still under control, and are you free of fluid, nerve, and thyroid warning signs? If yes, you are in the physiologic lane. And a tell worth being honest about: the more drugs you need just to tolerate it (insulin sensitizers, thyroid meds, diuretics), or the more you are making excuses to push through side effects, the further you have drifted from replacement and the closer you are to the risk zone.

Where it comes from changes everything

Clinical In the US, HGH is federally restricted, and non-medical use is not authorized. Anecdotal Beyond the legal issue, the gray market is full of counterfeit, underdosed, and contaminated pens and kits. With HGH, source quality can flip the entire risk picture: you cannot dose or monitor safely if you do not actually know what is in the vial. This is not a footnote.

The out-of-the-box angle you raised

Offsetting the blood-sugar downside

Since GH's main real drawback is that it raises blood sugar and insulin resistance, the smart question is: what can you pair with it to push insulin sensitivity the other way? The logic is strong. Be clear-eyed, though, that only one of these pairings has actually been tested in a human trial. Everything else is mechanism plus community practice, labeled as such.

Metformin

Clinical (1 direct combo RCT)

The classic insulin sensitizer, and the only companion actually studied alongside GH.

For
  • An 18-month randomized trial gave GH + metformin specifically to cover GH's diabetogenic effect; the combo improved insulin-sensitivity markers (raised adiponectin +32%) where metformin alone did not (Herrmann 2005)
  • Cheap, oral, decades of safety data
Against
  • The trial was small (about 14 men) - proof of concept, not a large outcome study
  • GI side effects; needs its own basic monitoring

Label: the single best real-world support for this whole pairing idea. Clinical

Retatrutide / GLP-1s (tirzepatide, semaglutide)

Pairing = anecdotal

Powerful weight loss and better glycemia; the community's go-to counterweight to GH's blood-sugar effect.

For
  • Retatrutide (triple agonist) drove up to -24% body weight with better blood pressure, cholesterol, glucose and insulin in its phase-2 trial (Jastreboff 2023) Clinical
  • Exactly the metabolic direction that offsets GH; bodybuilders already pair GLP-1s with GH for glucose control Anecdotal
Against
  • No trial has tested GLP-1 + HGH together. The pairing is community practice, not proven Anecdotal
  • GLP-1s cause meaningful lean-mass loss (~6 kg), which partly fights GH's whole point unless you train hard Clinical

Label: proven individually, unproven as a combo. Reasonable idea, not established.

MOTS-c

Mechanistic / preclinical

A mitochondrial-derived peptide that activates AMPK, the "exercise-mimetic" insulin-sensitivity angle.

For
  • In mice it activated AMPK and prevented both age-related and diet-induced insulin resistance and obesity (Lee 2015) Clinical (animal)
  • Points the opposite way to GH on glucose while being muscle-sparing - conceptually a clean counterweight
Against
  • No human trials of MOTS-c as a drug, and zero studies with GH. This is mouse data extrapolated Anecdotal when used as a stack

Label: exciting mechanism, preclinical only. Treat a "MOTS-c + HGH" stack as an experiment, not a protocol.

Berberine

Anecdotal (in this context)

The "natural metformin," an AMPK activator with its own glycemic data.

For
  • Has standalone human glycemic evidence; cheap and accessible
Against
  • No study of berberine + GH at all; the pairing is pure community rationale Anecdotal

Label: plausible, untested alongside GH.

The honest headline for this section

Pairing HGH with an insulin sensitizer is mechanistically sound, and metformin has one small human trial behind it. MOTS-c (mouse), Retatrutide/GLP-1s (proven alone), and berberine as GH companions are rationale and community practice, not tested combinations. Great thinking, worth a provider conversation, but do not sell it as proven.

Clinical And the subtle part: insulin is not purely the villain here. Portal insulin actually helps the liver respond to GH and make IGF-1, so crushing insulin too hard can blunt the IGF-1 you are after, while stacking insulin amplifies GH/IGF-1 biology (and the "GH gut" risk). So the goal is not "take sensitizers so I can push GH higher." It is the lowest GH dose that gets IGF-1 to mid-normal while your glucose stays controlled without needing rescue drugs.

More out-of-the-box angles

Other ways people use it well

  • Low-dose GH for tendon, skin, and connective tissue. Clinical Because the GH/IGF-1 axis stimulates tendon collagen more than muscle (Heinemeier 2012), a low, careful dose aimed at recovery and tissue quality is a legitimate, under-used angle - distinct from chasing size.
  • Pairing with BPC-157 for tendon repair. Clinical (animal) BPC-157 actually upregulates the growth-hormone receptor in tendon cells, a real molecular rationale for synergy. But human BPC-157 evidence is limited to case reports Anecdotal, so treat the stack as promising rat data plus community practice.
  • Timing around sleep and away from carbs/insulin. Clinical physiology (GH peaks in deep sleep, is blunted by insulin); Anecdotal the specific "inject fasted before bed" protocol is coach advice that aligns with the physiology.
  • Thyroid support. Clinical GH shifts T4 to T3, so checking thyroid after starting is evidence-based; Anecdotal the habit of adding T3/T4 is community protocol.

The question a lot of you have

Does HGH improve your eyesight?

Honest answer: there is no evidence HGH improves visual acuity in adults. Clinical In fact, adults with lifelong severe IGF-1 deficiency still had normal acuity (Faro 2017), so the axis is not a lever for sharpening normal vision. If your eyesight feels sharper after starting, the likely reasons are:

  • A temporary refractive shift Clinical - GH's fluid retention measurably changes corneal thickness and eye hydration (Magalhaes 2026), which can make vision feel crisper for a while. It is optics, not a healed retina, and it can drift back.
  • Less dry eye, better sleep, less eye strain Clinical (IGF-1 supports the tear film; tear IGF-1 falls with age, Patel 2018), plus plain expectation.

The caveat that matters more than the perk

The stronger, better-established eye effect of GH/IGF-1 is promoting retinal blood-vessel growth - it can worsen proliferative diabetic retinopathy Clinical. If you have diabetes or any retinopathy, treat HGH as a vision risk, not a tonic, and get a dilated retinal exam. For everyone: enjoy the subjective boost, but get a real eye exam to baseline your acuity and your retina while you are on it.

The support layer, graded

What genuinely helps, honestly

Solid

IGF-1 + glucose monitoring, resistance training, protein, sleep

The foundation. Monitoring keeps you in the safe window; training and protein make the anabolic signal count and offset any lean-mass drag from a GLP-1.

Reasonable

Metformin (if glucose drifts), thyroid support (if labs shift)

Evidence-guided companions for HGH's two most predictable side effects. Provider-directed.

Unproven

MOTS-c, berberine, BPC-157 stacks alongside GH

Interesting mechanism or animal data, no human combination evidence. Fine to explore knowingly; do not treat as proven.

Avoid

Megadosing, insulin stacking, chasing a supra-normal IGF-1

This is the road to GH gut, insulin resistance, and the acromegaly spectrum. The exact thing to not do.

Turn this into action

Questions to ask yourself

Do I actually know my IGF-1, and is it mid-normal or supra-normal?

Am I tracking fasting glucose / A1c, given GH raises blood sugar?

Is my dose physiologic, or am I creeping toward bodybuilder territory?

Do I have any diabetes, retinopathy, or cancer history that changes my risk?

Am I doing this with a provider and real bloodwork, or winging it?

Questions to ask your provider

What IGF-1 range are we targeting, and how often will we recheck it?

Given my glucose, should we add metformin or a GLP-1, and monitor A1c?

Should we check my thyroid (free T4/T3) after starting?

Do my eyes need a baseline exam, especially any retinopathy risk?

The numbers to know

  • IGF-1 - the master dial. Keep it mid-normal for your age; never chase supra-normal.
  • The metabolic panel - fasting glucose, HbA1c, and ideally fasting insulin, triglycerides, and waist circumference. GH's most predictable cost is metabolic, and fasting insulin often drifts before glucose does. If you are higher-risk, a continuous glucose monitor (CGM) tells you far more than how you feel.
  • Free T4 / T3, blood pressure - shift with GH; worth tracking.
  • A dilated eye exam - baseline acuity and retina, especially with any diabetes.

Call a provider now

HGH problems build slowly, but do not wait on these:

  • New persistent headache or vision changes (possible raised brain pressure)
  • Rapidly rising blood sugar or diabetes symptoms (thirst, urination, blurriness)
  • Chest pain, shortness of breath, or swelling
  • A new or growing lump
  • Numbness/weakness in the hands that is worsening
  • A visibly distending abdomen or organ-area discomfort

Most of these are dose-driven and reversible if caught early. The fix is almost always: lower the dose, get IGF-1 back to mid-normal, and get checked.

The BlessUp take

A scalpel, not a sledgehammer.

HGH is one of the few compounds where the same molecule is either genuinely restorative or genuinely damaging, and you choose which by the dose. Run low, aim IGF-1 for the middle of the range, watch your blood sugar, respect your eyes, and it can support recovery, connective tissue, body composition, and how you feel. Chase supra-normal IGF-1 like a stage bodybuilder and you buy yourself organ growth, insulin resistance, and the acromegaly spectrum.

The BlessUp way is the same as always: know your numbers, respect the biology, and refuse to overdo it. The insulin-sensitivity companions are smart thinking, and the honest state of the evidence is that metformin has real support and the rest is promising theory. Bring the ideas to a provider, keep it physiologic, and let the growth be the good kind.

Education only, not medical advice, and not a recommendation to use a federally-restricted drug. HGH decisions require a licensed provider, your history, and monitoring bloodwork. Every dose and compound named is an example for discussion, never a prescription. For research and educational purposes, adults 21 and over.

Stand strong, lion.

The evidence

Sources

Separated so you can see what is proven from what is reported. Clinical items are indexed in PubMed; links go to the DOI. Anecdotal items are named and linked so you can judge them yourself.

Clinical sources

  1. Rudman D, et al. Effects of human growth hormone in men over 60. N Engl J Med. 1990. doi:10.1056/NEJM199007053230101
  2. Liu H, et al. Safety and efficacy of growth hormone in the healthy elderly (systematic review). Ann Intern Med. 2007. doi:10.7326/0003-4819-146-2-200701160-00005
  3. Blackman MR, et al. GH and sex steroids in healthy aged men and women (RCT). JAMA. 2002. doi:10.1001/jama.288.18.2282
  4. Newman CB, et al. Low- vs high-dose GH on body composition and lipids in GHD (meta-analysis). Pituitary. 2015. doi:10.1007/s11102-014-0571-z
  5. Davidson P, et al. GH replacement and bone mineral density (meta-analysis). Clin Endocrinol. 2004. doi:10.1111/j.1365-2265.2004.01935.x
  6. Nass R, et al. Oral ghrelin mimetic (MK-677) in healthy older adults (RCT; glucose/insulin sensitivity). Ann Intern Med. 2008. doi:10.7326/0003-4819-149-9-200811040-00003
  7. Teichman SL, et al. Prolonged stimulation of GH and IGF-1 by CJC-1295, a long-acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2006. doi:10.1210/jc.2005-1536
  8. Raun K, et al. Ipamorelin, a novel, selective GH secretagogue (pharmacology). Eur J Endocrinol. 1998. doi:10.1530/eje.0.1390552
  9. Falutz J, et al. Tesamorelin for reducing visceral fat in HIV-associated lipodystrophy (phase 3). N Engl J Med / J Clin Endocrinol Metab. 2007/2010. doi:10.1056/NEJMoa072375
  10. Herrmann BL, et al. rhGH + metformin on adiponectin / insulin sensitivity (RCT). Horm Metab Res. 2005. doi:10.1055/s-2005-861036
  11. Lee C, et al. MOTS-c promotes metabolic homeostasis and reduces insulin resistance (mouse). Cell Metab. 2015. doi:10.1016/j.cmet.2015.02.009
  12. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity (phase 2). N Engl J Med. 2023. doi:10.1056/NEJMoa2301972
  13. Locatelli JC, et al. Incretin weight-loss therapy and body composition (lean-mass loss). Diabetes Care. 2024. doi:10.2337/dci23-0100
  14. Mukama T, et al. IGF-1 and cancer, CVD and all-cause mortality (EPIC-Heidelberg; U-shaped). J Clin Endocrinol Metab. 2023. doi:10.1210/clinem/dgad212
  15. Maione L, et al. Acromegaly management and comorbidities over three decades (French Registry). Eur J Endocrinol. 2017. doi:10.1530/EJE-16-1064
  16. Huang R, et al. Cardiac dysfunction in acromegaly. Front Endocrinol. 2023. doi:10.3389/fendo.2023.1260842
  17. Suslin IA, et al. Abdominal hypertrophy syndrome (palumboism): characteristics and pathophysiology. Cureus. 2024. doi:10.7759/cureus.72026
  18. Heinemeier KM, et al. GH/IGF-I axis and tendon/muscle matrix adaptation in humans. Scand J Med Sci Sports. 2012. doi:10.1111/j.1600-0838.2012.01459.x
  19. BPC-157 enhances GH-receptor expression in tendon fibroblasts (rat). PMC6271067. pmc.ncbi.nlm.nih.gov/articles/PMC6271067
  20. Ortiga-Carvalho TM, et al. Hypothalamus-Pituitary-Thyroid Axis (T4-to-T3). Compr Physiol. 2016. doi:10.1002/cphy.c150027
  21. Faro ACN, et al. Ocular findings in adults with lifelong IGF-1 deficiency. Growth Horm IGF Res. 2017. doi:10.1016/j.ghir.2017.04.002
  22. Magalhaes PL, et al. GH therapy and ocular biometry (systematic review/meta-analysis). Eye (Lond). 2026. doi:10.1038/s41433-025-04220-3
  23. Patel R, et al. Age-related decline in tear IGF-1 and dry eye. Growth Horm IGF Res. 2018. doi:10.1016/j.ghir.2018.02.001
  24. Wilkinson-Berka JL, et al. GH, IGF and somatostatin in diabetic retinopathy. Curr Med Chem. 2006. doi:10.2174/092986706778773086
  25. Takala J, et al. Increased mortality associated with growth hormone treatment in critically ill adults (high-dose GH). N Engl J Med. 1999;341(11):785-92. doi:10.1056/NEJM199909093411102
  26. Molitch ME, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011. doi:10.1210/jc.2011-0179
  27. Yuen KCJ, et al. AACE/ACE Guidelines for Management of Growth Hormone Deficiency in Adults. Endocr Pract. 2019. doi:10.4158/GL-2019-0405

Anecdotal / community sources (labeled, judge for yourself)

  • Off-label GLP-1 use among online bodybuilders (peer-reviewed netnography of community practice). Int J Drug Policy 2025. sciencedirect.com
  • HormoneFitness (clinic blog) - pairing GLP-1s with GH for blood sugar. hormonefitness.com
  • Ageless Forever (clinician) - GH low-dose start, titration and monitoring. agelessforever.net
  • Muscle & Brawn / Predator Nutrition - "GH gut"/palumboism explainers (no primary evidence cited). muscleandbrawn.com
  • GlobalRPH - BPC-157/TB-500 background and the limited human evidence. globalrph.com

Built from our internal research (verified PMIDs) and merged with a parallel ChatGPT research pass. The guiding safety principle throughout: keep IGF-1 mid-normal and glucose controlled with no fluid, nerve, or thyroid warning signs. The more drugs you need just to tolerate it, the further you have drifted from the safe, physiologic route.